Prevention of Experimental Colitis by a Selective Inhibitor of the Immunoproteasome

Michael Basler, Maya Dajee, Carlo Moll, Marcus Groettrup and Christopher J. Kirk

J Immunol published online 4 June 2010
http://www.jimmunol.org/content/early/2010/06/04/jimmunol.0903182

Supplementary Material
http://www.jimmunol.org/content/suppl/2010/06/02/jimmunol.0903182.DC1

Subscription
Information about subscribing to The Journal of Immunology is online at:
http://jimmunol.org/subscription

Permissions
Submit copyright permission requests at:
http://www.aai.org>About/Publications/JI/copyright.html

Email Alerts
Receive free email-alerts when new articles cite this article. Sign up at:
http://jimmunol.org/alerts
Prevention of Experimental Colitis by a Selective Inhibitor of the Immunoproteasome

Michael Basler,*† Maya Dajee,‡ Carlo Moll,§ Marcus Groettrup,*† and Christopher J. Kirk§

The proteasome, a multicatalytic protease, is responsible for the degradation of intracellular proteins. Stimulation of cells with inflammatory cytokines, such as IFN-γ, leads to the replacement of the constitutive catalytic proteasome subunits by the inducible subunits low molecular mass polypeptide (LMP)2 (β1i), multicatalytic endopeptidase complex-like-1 (β2i), and LMP7 (β5i), which are required for the production of certain MHC class I-restricted T cell epitopes. In this study, we investigated the effect of immunoproteasomes on the development of dextran sulfate sodium-induced colitis. Colitis induction in LMP2-, LMP7-, and multicatalytic endopeptidase complex-like-1-deficient mice caused reduced weight loss compared with wild-type mice. Although colon lengths were shortened in wild-type mice, no reduction was observed in immunoproteasome-deficient mice. In accordance with this, proinflammatory cytokines, such as TNF-α and IL-1β, were not upregulated in these mice. Blockage of LMP7 by a novel LMP7-selective inhibitor (PR-957) strongly reduced pathological symptoms of dextran sulfate sodium-induced colitis. Production of numerous cytokines in PR-957–treated mice was suppressed, resulting in reduced inflammation and tissue destruction. Taken together, these results demonstrate that an immunoproteasome-specific inhibitor can be used to attenuate autoimmune diseases like colitis. The Journal of Immunology, 2010, 185: 000–000.

I

flammatory bowel disease (IBD) refers to a group of chronic inflammatory disorders of the gastrointestinal tract that affect ∼1 million people in the United States and 2 million people in Europe (1). In humans, the two key forms of IBD are Crohn’s disease (CD) and ulcerative colitis (UC). The hallmark of IBD is chronic, uncontrolled inflammation that can affect any part of the gastrointestinal tract in CD and only the colon in UC (2). Both diseases are characterized by mucosal inflammation, diarrhea, hematochezia, weight loss, and abdominal pain. The pathogenesis of IBD involves the interplay of environmental, genetic, microbial, and immune factors that results in chronic intestinal inflammation. Current treatment options include 5-aminosulfonic acid, antibiotics, corticosteroids, nutritional therapy, as well as immunomodulators to induce and maintain remission (3–5). Although such treatments are effective in many cases of CD and UC, a large patient population suffers intolerable side effects, relapse, or fails to respond altogether. Therefore, further investigation of novel therapeutics is warranted. IBDs are hypothesized to result from abnormal immune responses to Ags derived from intestinal microbiota, which seem to contribute to the recruitment and activation of lamina propria macrophages and T cells (6, 7). Initiation and perpetuation of inflammation in UC and CD may be regulated, in part, by an increased secretion of proinflammatory cytokines, such as IL-1β and TNF-α, by these cells (8).

Multiple cellular processes, such as cell cycle regulation (9), apoptosis (10), cell adhesion (11), transcription (12), angiogenesis (13), and generation of peptides from intracellular Ags that are presented to cytotoxic T lymphocytes by MHC class I (14, 15), are controlled by the proteasome. It is the major cytosolic endoprotease in eukaryotes, consisting of α and β subunits that build a barrel-shaped complex of four rings with seven subunits each (called 20S proteasome) (16). The outer two rings consist of α subunits; the inner two rings consist of β subunits, which bear the proteolytically active centers. Three β subunits (β1, β2, and β5) are responsible for three catalytically distinct peptidase activities: caspase-like, trypsin-like, and chymotrypsin-like activities, respectively (17, 18). In the context of IFN-γ and TNF-α, the inducible proteolytically active subunits low molecular mass polypeptide (LMP) 2 (β1i), multicatalytic endopeptidase complex-like (MECL)-1 (β2i), and LMP7 (β5i) are incorporated into the so-called “immunoproteasome” (19). These immunosubunits play a role in class I ligand generation, in establishing the naïve CD8–T cell repertoire, and in altering the cytotoxic T cell response (20, 21). In a recent study, a novel function of immunoproteasomes, independent of class I Ag presentation, was revealed. An LMP7-selective epoxyketone proteasome inhibitor (PR-957) blocked cytokine production and attenuated the progression of experimental arthritis (22, 23).

In this study, we investigated the role of immunoproteasomes in a murine model of colitis. Immunoproteasome-deficient mice developed only mild symptoms. Blockage of LMP7 by a selective inhibitor (PR-957) led to attenuated colitis manifested by reduced body weight loss and decreased cytokine production and tissue destruction. Our results suggest that selective inhibition of LMP7 by PR-957 has the potential to attenuate IBD in humans.

Downloaded from http://www.jimmunol.org by guest on April 18, 2017
Materials and Methods

**Mice**
C57BL/6 mice (H-2b) were purchased from Charles River (Sulzfeld, Germany). MECL-1 (21), LMP2 (24), and LMP7 (25) gene-targeted mice were kindly provided by Dr. John J. Monaco (Department of Molecular Genetics, Cincinnati Medical Center, Cincinnati, OH). Gene knockout mice were backcrossed to C57BL/6 background for ≥10 generations. Female mice were kept in specific pathogen-free facility and used at 6–10 wk of age. Animal experiments were approved by the review board of Regierungspärisium Freiburg or were done under protocols approved by an institutional animal care and use committee.

**Proteasome inhibition in mice**
PR-957 (22) was formulated in an aqueous solution of 10% (v/w) sulfoxbuty lethyl-β-cyclodextrin and 10 mM sodium citrate (pH 6) and administered to mice as an s.c. or i.v. bolus dose of 6, 12, or 20 mg/kg (in a volume of 100 µl). PR-825 was dissolved in 2% ethanol in saline and administered as an s.c. bolus dose of 2 mg/kg (in a volume of 100 µl).

**Induction of colitis**
Colitis was induced in 8–10-wk-old mice by adding 2% dextran sulfate sodium (DSS) (m.w. 36,000–50,000; MP Biomedicals, Solon, OH) to the drinking water, beginning at day 0 for 5 d; thereafter, they were given regular drinking water. Body weight was measured daily throughout the experiment. In two sets of experiments (Figs. 1, 6A), 3% DSS was added to the drinking water for 7 d. Studies were carried out in both facilities in accordance with regulatory standards at each facility (University of Constance, Konstanz, Germany and Proteolis, Inc., South San Francisco, CA).

**CD4+ cell stimulation**
T cells from splenocytes of C57BL/6 or LMP7-deficient mice were isolated with antiCD4-coated microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany). Cells were incubated with 200 nM PR-957 or 125 nM PR-825 for 1 h at 37˚C. Washed cells (4 × 10^7/well) were stimulated with plate-bound anti-CD3 (4 µg/ml, clone17A2; eBioscience, San Diego, CA) for 2 d. IL-17 (eBioscience) and IFN-γ (BD Biosciences, San Jose, CA) in the supernatant were determined by ELISA, according to the manufacturer’s protocol.

**Flow cytometry**
Flow cytometry was performed exactly as previously described (26). Abs to CD3, CD8, CD4, CD19, and CD11c were purchased from BD Biosciences. Flow cytometry was performed on a BD FACSCalibur (BD Biosciences) using the BD FACSDiva software (BD Biosciences, San Jose, CA).

**Proteasome active-site ELISA**
A proteasome active-site ELISA was used to monitor inhibition of constitutive and immunoproteasome active sites in mouse colon tissue, and it was performed as described previously (22).

**Quantitative real-time RT-PCR**
Real-time RT-PCR was used to quantify cytokine expression levels in mouse colons. Total RNA was extracted from colon of mice using a NucleoSpin RNA II kit (MACHEREY-NAGEL, Düren, Germany). One microgram of total RNA was reverse transcribed using oligonucleotide (dT) primers and the reverse transcription system (Promega, Madison, WI). Quantitative PCR was performed with the LightCycler instrument, using the LightCycler Fast Start DNA Master SYBR Green I reaction mix (both from Roche Diagnostics, Mannheim, Germany). The experiments were performed on an ABI PRISM 7900 sequence detection system under the following conditions: 1 cycle of 50˚C (2 min), followed by 95˚C (10 min), 40 cycles of 95˚C (15 s), and 60˚C (1 min). All reactions were performed in triplicate, and the experiments were repeated three times. Ct values were normalized to β-actin.

**Histological analysis**
Colons were fixed in 4% formalin in phosphate buffer (55 mM Na2HPO4, 12 mM NaH2PO4). The fixed tissues were dehydrated and embedded in paraffin. Seven-micrometer sections were stained with H&E and scored by a pathologist in a blind manner. The degree of inflammation and epithelial injury on microscopic cross-sections of the colon was graded semiquantitatively: 0; none; 1; minimal; 2; mild; 3; moderate; and 4, severe.

**Statistical analysis**
The statistical significance of the differences was determined using the Student t test or one-way ANOVA. For ANOVA, we used the Bonferroni post hoc analysis to compare treatment groups. All statistical analyses were performed using GraphPad Prism Software (version 4.03) (GraphPad, San Diego, CA). Statistical significance was achieved when p < 0.05.

**Results**
DSS-induced colitis upregulates immunoproteasome subunits
Compared with healthy humans, CD patients show a strong upregulation of the immunosubunits β1i and β2i in the inflamed mucosa (27). To investigate whether comparable results could be found in DSS-induced colitis, immunoproteasome content in colon of diseased mice was analyzed by a proteasome active-site ELISA. We compared the relative levels of proteasome active sites in colon tissue lysates from healthy mice with those challenged with DSS (3%).

**Reduced severity of DSS-induced colitis in LMP7-deficient mice**
To analyze whether upregulation of immunosubunits in colon of diseased mice is due to an induction of immunosubunits by inflammatory cytokines produced by infiltrating immune cells or whether immunoproteasome are crucial, per se, in disease development, we induced colitis in LMP7-deficient mice by oral administration of DSS in drinking water for 5 d (Fig. 2). Body weight of the mice was recorded for 14 d. Although wild-type (WT) mice had lost ~20% of body weight by day 9, LMP7-deficient mice were fully protected from weight loss. Hence, we conclude that immunoproteasome upregulation in colitis is not only a side effect due to induction by cytokines produced by infiltrating immune cells, but also that LMP7 plays a crucial role in colitis development.

**Immunosubunit deficiency protects mice from DSS-induced colitis**
It was reported that LMP7-deficient mice have decreased incorporation of LMP2 and MECL-1 into proteasomes (28). Therefore, the decreased loss in body weight seen in Fig. 2 might originate from decreased LMP2 or MECL-1 expression. DSS-induced colitis was analyzed in LMP2- and MECL-1-deficient mice to determine whether they are protected similarly to LMP7-/- mice. LMP7-, LMP2-, and MECL-1-deficient mice showed less weight loss compared with C57BL/6 WT mice (Fig. 3). Although LMP2-deficient mice lost ~10% of weight, MECL-1-deficient mice were fully protected. DSS-induced colitis is associated with reduced...
colon length in diseased mice. To investigate whether the decreased body weight loss in LMP2-, LMP7-, and MECL-1–deficient mice is accompanied by an altered colon length, the latter parameter was measured in DSS-treated mice on day 9 postinduction (Fig. 4A). Colon length was reduced in DSS-treated C57BL/6 mice by ∼2 cm compared with untreated naive mice. MECL-1– and LMP7-deficient mice showed no significant alteration in colon length, whereas LMP2-deficient mice had a slight reduction in length. Nevertheless, the colon length of LMP2-deficient mice was still clearly increased compared with DSS-treated C57BL/6 WT mice.

IBD is accompanied by the accumulation of a variety of inflammatory cells and the release of several soluble mediators of inflammation, such as reactive oxygen species, lipid mediators, proteases, and cytokines. Among these, a number of proinflammatory cytokines were demonstrated to be elevated in colitis (29) and play an important role in the development of mucosal inflammation. To investigate whether inflammation is altered in immunoproteasome-deficient mice with colitis, TNF-α, IFN-γ, and IL-1β, -6, -17, and -23 expression was determined by real-time PCR in colon on day 9 after colitis induction (Fig. 4B). Cytokines were upregulated in WT mice, whereas MECL-1–, LMP2, and LMP7-deficient mice showed no significant increase compared with healthy untreated

**FIGURE 1.** Proteasome subunit expression in colons of normal and diseased C57BL/6 mice. Colitis was induced in C57BL/6 mice by oral administration of 3% DSS in drinking water for 7 d, followed by a recovery period of 7 d without DSS challenge. On day 8, colons were removed, lysed, and analyzed by ELISA for expression of proteasome active sites. Data are presented as mean ± SEM for luminescent signal/μg of lysate from triplicate samples. Data are from three DSS-challenged and three nonchallenged, age-matched controls. The experiments were performed twice, yielding similar results.

**FIGURE 2.** Body weight change of C57BL/6 and LMP7-deficient mice with DSS-induced colitis. Colitis was induced in C57BL/6 and LMP7-deficient mice by oral administration of 2% DSS in drinking water for 5 d. Body weight of individual mice was monitored daily. Percent weight loss (y-axis) is plotted versus time (x-axis). Data points represent mean ± SD of five mice. The experiments were performed three times, yielding similar results. *p < 0.01; **p < 0.001.

**FIGURE 3.** Change in body weight of C57BL/6 and LMP7-, LMP2-, and MECL-1–deficient mice with DSS-induced colitis. Colitis was induced by oral administration of 2% DSS for 5 d. Body weight of individual mice was monitored daily. Percent weight loss (y-axis) is plotted versus time (x-axis). Data points represent mean ± SD of five mice. The experiments were performed twice, yielding similar results. *p < 0.05; **p < 0.01; ***p < 0.001.
WT mice. The degree of inflammation and epithelial injury on microscopic cross-sections of the colon was graded semiquantitatively from 0 to 4 (Fig. 4C, 4D). In contrast to WT mice, immunoproteasome-deficient mice had only mild signs of inflammation and epithelial damage. Taken together, LMP2-, LMP7-, and MECL-1–deficient mice display a strongly attenuated form of DSS-induced colitis.

**An LMP7-selective inhibitor reduces symptoms of DSS-induced colitis**

Recently, we demonstrated that selective inhibition of LMP7 by PR-957 blocked the production of IL-23 by activated monocytes and the production of IFN-γ and IL-2 by T cells (22). In mouse models of rheumatoid arthritis, PR-957 treatment reversed signs of disease and resulted in reductions of cellular infiltration, cytokine production, and autoantibody levels. Similar to rheumatoid arthritis, IBDs are characterized by infiltration of leukocytes and tissue destruction by immune mediators, like cytokines. PR-957 is an LMP7-selective peptide-ketoepoxide proteasome inhibitor that is 20- to 40-fold more selective for LMP7 over the next most sensitive sites, β5 or LMP2 (22). Selective inhibition of LMP7 by PR-957 occurs at doses ranging from 1–10 mg/kg body weight in blood and kidney. The maximum tolerated dose of PR-957 in mice...
is 30 mg/kg body weight, indicating that inhibition of LMP7 is well tolerated (22). To test whether PR-957 is able to block LMP7 in colon, the inhibitor was administered i.v. or s.c. at 6 or 20 mg/kg. The proteasome active-site selectivity of PR-957 was determined with a subunit-specific ELISA to quantify occupied proteasome active sites in colon (Fig. 5A). LMP7 activity was reduced to ~10% of untreated colon, independent of dose and injection route. B5 activity was reduced by ~50%. To test whether PR-957 can attenuate DSS-induced colitis, mice were treated daily with 12 mg/kg PR-957 for 9 d. Untreated mice lost ~25% of body weight between days 5 and 9 (Fig. 5B). In contrast, mice treated with the LMP7 selective inhibitor PR-957 showed only minor (~5%) body weight loss at day 9 postinduction. To test whether long-term treatment affects the viability of immune cells, mice were treated daily with PR-957 for 9 d. On day 10, T cells (CD3+, CD8+, and CD4+), B cells (CD19+), and dendritic cells (CD11c+) were analyzed by flow cytometry (Supplemental Fig. 1). The percentage of CD11c+ and CD19+ cells was decreased slightly in spleen of PR-957–treated mice, and a concomitant increase in CD3+ and CD8+ cells was observed. Additionally, Annexin V/propidium iodide staining 24 h after PR-957 treatment demonstrated that inhibitor treatment did not lead to increased cell death of CD4+, CD19+, or CD11c+ cells (Supplemental Fig. 2). Hence, the reduction in weight loss in PR-957–treated mice observed in Fig. 5B cannot be explained simply by the elimination of immune cells.

Targeting the proteasome by the proteasome inhibitor bortezomib reduced colitis development in a rat model (30). Because bortezomib mediates equipotent inhibition of B5 and LMP7, we investigated whether the selective B5 inhibitor PR-825 (22) could reduce the severity of colitis development. Mice were treated daily with 2 mg/kg PR-825 or vehicle for 21 d. Weight loss in PR-825 mice was similar to that in vehicle-treated mice (Fig. 5C). These results indicated that LMP7 inhibition underlies the reduced colitis development in bortezomib-treated mice. Consistent with the marginal weight loss in PR-957–treated mice (Fig. 5B), colon length was only reduced in untreated mice, whereas inhibitor-treated mice displayed a colon length comparable to naive animals (Fig. 5D). Histological analysis of colon cross-sections revealed reduced inflammation and epithelial injury (Fig. 5E, 5F).

**PR-957 attenuates cytokine production in colon of DSS-treated mice**

We have shown that PR-957 blocks cytokine production in activated lymphocytes and monocytes (22). Among the tested cytokines, IL-23 was the most sensitive to PR-957 treatment in LPS-stimulated...
PBMCs from healthy donors and patients with rheumatoid arthritis. IL-23 has been implicated in intestinal inflammation (31, 32) and elicits numerous effector molecules, most notably IL-17 and TNF-α (33). Because Th17 differentiation is blocked by PR-957 (22), we assume that Th17-associated cytokine production is altered in PR-957-treated mice with DSS-induced colitis. Indeed, cytokine profiling of colon tissue by RT-PCR on day 7 showed that PR-957 treatment decreased the expression of multiple inflammatory mediators, including IL-1β and -23 (Fig. 6A). Inducible NO synthase and cyclooxygenase-2 are important enzymes that mediate inflammatory processes and have been associated with the pathogenesis of certain types of human cancers, as well as inflammatory disorders. Both enzymes were significantly reduced in PR-957–treated mice, indicating reduced leukocyte infiltration and inflammation in colon tissue. To test whether PR-957 and PR-825 directly inhibit cytokine secretion from activated WT or LMP7-deficient cells, CD4+ T cells were stimulated with plate-bound CD3. PR-957 blocked the production of IL-17 and IFN-γ in WT but not LMP7-deficient CD4+ T cells (Fig. 6B). The lack of effect in LMP7-deficient cells indicates that PR-957 affects cytokine production through specific inhibition of LMP7. The fact that LMP7-deficient and WT splenocytes did not differ in IL-17 or IFN-γ production may be the result of compensatory incorporation of β5 in proteasomes from LMP7-deficient cells. Indeed, treatment of LMP7-deficient splenocytes with the β5-selective inhibitor PR-825 reduced cytokine production only in LMP7-deficient cells. Taken together, selective inhibition of LMP7 by PR-957 reduced the symptoms of DSS-induced colitis, manifested by decreased weight loss, colon tissue destruction, inflammation, and cytokine production.

**Discussion**

Because of the role of proteasomes in the regulation of numerous cellular processes, inhibition of the proteasome is an attractive strategy for anticancer therapy. Bortezomib, which targets the constitutive proteasome and immunoproteasome, is the first clinically approved proteasome inhibitor for relapsed and/or refractory myeloma and mantle cell lymphoma (34). Recently, novel proteasome inhibitors preferentially targeting subunits of the immunoproteasome were described (22, 35–37). An LMP2-specific inhibitor attenuated proliferation in myeloma patient samples and other hematologic malignancies, although the chymotrypsin-like activity associated with the subunits β5 and β5i was also reduced at the concentrations used (37). Another study investigated the effect of an LMP7-selective inhibitor (PR-957) on the development of experimental arthritis in two mouse models (22). PR-957 treatment reversed signs of disease and resulted in reductions in cellular infiltration, cytokine production, and autoantibody levels. Additionally, selective inhibition of LMP7 by PR-957 blocked the production of IL-23 by activated monocytes and the production of IFN-γ and IL-2 by T cells, whereas the inhibition of β5 did not substantially affect cytokine release. Furthermore, LMP7 inhibition prevented the production of cytokines driving Th17 generation and IL-17 production in T cells cultured in the presence of polarizing cytokines. Because of a unique role for LMP7 in controlling cytokine production, it provides a therapeutic rationale for targeting LMP7 in autoimmune disorders. Therefore, the impact of immunoproteasomes in DSS-induced colitis was investigated. Induction of colitis upregulated the immunosubunits LMP2, LMP7, and MECL-1 (Fig. 1). Because colitis induction leads to an infiltration of immune cells into colon tissue, production of cytokines by these cells might lead to an induction of immunoproteasomes in colon by IFN-γ or TNF-α, as seen in Fig. 1. Alternatively, cells of hematopoietic origin, particularly lymphocytes and monocytes, constitutively express immunoproteasome subunits (38). Infiltration of such cells might contribute to the upregulation of LMP2, LMP7, and MECL-1 (Fig. 1). Comparable results were obtained from CD patients, who showed high LMP2 and MECL-1 expression in inflamed mucosa (27). Because LMP7 is already expressed in high amounts in healthy control patients, no upregulation of this subunit was observed in CD patients in two additional studies (39, 40). Induction of colitis by oral administration of DSS in the drinking water of LMP2-, LMP7-, and MECL-1–deficient mice revealed a nearly complete protection of these mice compared with WT mice (Figs. 2, 3). Colon inflammation, tissue destruction, and upregulation of proinflammatory cytokines were barely detectable in these mice (Fig. 4). Similar results were found in the LMP2 knockout mouse by another group (41), which demonstrated that LMP2 expression contributes to the pathogenesis of DSS-induced colitis in mice. In a model of murine autoimmune encephalomyelitis, it was demonstrated that the immunoproteasome is not required for the establishment of myelin oligodendrocyte glycoprotein–induced autoimmune encephalomyelitis (42), suggesting a contribution of the immunoproteasome in the etiology of IBD but not multiple sclerosis. Presumably, the prevention of DSS-induced colitis in immunoproteasome-deficient mice cannot be explained solely by an altered production of cytokines by T cells, because in vitro cytokine-secretion assays demonstrated that T cells derived from immunoproteasome-deficient mice produced similar amounts of cytokines as WT mice (Fig. 6B) (22). However, recent data suggest that immunoproteasomes might play a role in innate immunity. Production of IFN-α, IL-6 and -1β, and TNF-α was reduced in influenza A virus–infected bone marrow–derived dendritic cells derived from LMP2-deficient mice compared with those from WT mice (43). Challenge with DSS results in macrophage and granulocyte infiltration into intestinal submucosa and lamina propria (44). Therefore, altered activation or function of innate immune cells in immunoproteasome-deficient mice could explain the prevention of...
DSS-induced colitis in gene-deficient animals. However, the mucosa is a complex environment with a physiology that is regulated by a variety of cell types of nonhematopoietic origin. Experiments using bone marrow chimeras of immunoproteasome-deficient and WT mice could reveal whether immunoproteasome expression is essential in immune cells or in cells of nonhematopoietic origin, such as epithelial cells.

Instead of the gene-targeted immunoproteasome subunit, the respective constitutive counterpart is incorporated into proteasomes of LMP2-, LMP7-, or MECL-1-deficient mice. Furthermore, immunoproteasomes from knockout mice express altered incorporation of the remaining 20Si subunits. Therefore, increased incorporation of the constitutive subunits, not the immunoproteasome deficiency, might contribute to the reduced pathogenicity in these knockout mice (Figs. 2–4). An LMP7-selective inhibitor (PR-957) was used to analyze the direct influence of LMP7 on the development of colitis (Fig. 5). Administration of PR-957 attenuated symptoms of DSS-induced colitis, as determined by weight loss (Fig. 5B) and colon length (Fig. 5D). Inflammation in these mice was reduced (Figs. 5E, 5F, 6A), and the production of numerous cytokines was strongly impaired (Fig. 6A). Administration of a β5-selective inhibitor had no effect on colitis severity. Taken together, these data suggest that, despite the high basal expression of LMP7 in normal colon tissue (39, 40), LMP7 represents a targeted approach to the treatment of CD because of the unique role of the immunoproteasome in regulatory inflammatory responses. Our results indicated that LMP7 is directly involved in disease development, presumably as the result of regulation of cytokine production in inflammatory cells. Development and investigation of inhibitors for LMP2, or MECL-1, are warranted to analyze whether similar effects can be observed. Previous studies demonstrated a requirement for IL-23 in driving intestinal inflammation mediated by innate immune cells and T cells in murine colitis (31, 32, 45). A genome-wide association study in humans found a highly significant association between CD and the IL-23R gene. The investigators suggested blockade of the IL-23–signaling pathway as a rational therapeutic strategy for IBD (46). Because PR-957 blocked IL-23 production of human PBMCs (22) and IL-23 expression in inflamed colon tissue (Fig. 6A), the LMP7-selective inhibitor would be an extremely suitable candidate for such an approach. Th17 cytokines, such as IL-17 and -22, in combination with IL-23, play crucial roles in intestinal protection and homeostasis. TGF-β and IL-6, rather than IL-23, were shown to be the key cytokines directing Th17 cell development. It now seems that IL-23 is unnecessary in mice for the initiation of Th17 differentiation, but it is required for expansion and/or maintenance of the Th17 response (47). We speculate that PR-957 affects the Th17 axis in our model of colitis by attenuated polarization of CD4+ cells to Th17 cells and reduced maintenance of Th17 cells as the result of blocked IL-23 production. We demonstrated that PR-957 alters cytokine production in WT, but not in LMP7-deficient, CD4+ cells (Fig. 6B). In contrast, the selective β5c inhibitor PR-825 reduced cytokine secretion in LMP7-deficient CD4+ cells but not in WT cells. These data suggest that proteasome composition in CD4+ cells mainly consists of the immunoproteasome type, because no inhibition of cytokine release by PR-825 could be observed in WT cells.

Targeting the proteasome by the proteasome inhibitor bortezomib recently led to success in multiple mouse models of autoimmune disorders. Pharmacological inhibition with bortezomib ameliorated glomerulonephritis and prolonged the survival of two mouse strains with lupus-like disease (48), attenuated murine collagen-induced arthritis (49), reduced colitis development in a rat model (30), and ameliorated autoimmune encephalomyelitis in mice and rats in prophylactic and therapeutic treatment (50). It is well established that bortezomib inhibits NF-κB activation by blocking the degradation of the NF-κB inhibitor (IκB), leading to reduced expression of proinflammatory factors, such as cytokines and chemokines, and adhesion molecules on lymphoid cells. Hence, the observed effects in multiple models of autoimmune diseases might be due to an inhibition of the NF-κB pathway. In contrast, PR-957 does not inhibit NF-κB activity in a reporter cell line at selective concentrations, suggesting that LMP7 regulates cytokine production via NF-κB–independent pathways that remain to be elucidated (22).

In this study, we investigated the effect of a novel LMP7-selective inhibitor in a murine model of colitis. PR-957 prevented disease development at far less than the maximal tolerated dose and without notable toxic side effects; therefore, it holds great potential for the modulation of immune responses and for the suppression of autoimmune diseases like IBD.

Acknowledgments

We thank Ulrike Beck for excellent technical assistance.

Disclosures

M.D. and C.J.K. are (or were) employees of ProteoliX, Inc. (now Onyx Pharmaceuticals).

References


Supplementary Figures

Supplementary Figure 1

**Supplementary Figure 1.** Effect of long-term PR-957 treatment on T-cells, B-cells, or dendritic cells. Mice were daily treated with PR-957 (12mg/kg, s.c.). On day 9, spleen cells were harvested, stained for CD19, CD3, CD8, CD4, or CD11c and analyzed by flow cytometry. Shown are the percentages of CD19-, CD3-, CD8-, CD4-, or CD11c-positive cells of lymphocytes (y-axis) as determined by flow cytometry.
Supplementary Figure 2

**Supplementary Figure 2.** Effect of PR-957 treatment on T-cells, B-cells, or dendritic cells. Mice were treated with PR-957 (12mg/kg, s.c.) or vehicle. Next day, spleen cells were harvested, stained for CD4, CD19, or CD11c and Annexin V / propidium iodide (PI). Shown are the percentages of AnnexinV⁺/PI⁺ CD4-, CD19-, or CD11c-positive cells (y-axis) as determined by flow cytometry.